These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2539283)

  • 1. Immunological alterations associated with recurrent herpes simplex genitalis.
    Cauda R; Laghi V; Tumbarello M; Ortona L; Whitley RJ
    Clin Immunol Immunopathol; 1989 May; 51(2):294-302. PubMed ID: 2539283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes.
    Kim M; Osborne NR; Zeng W; Donaghy H; McKinnon K; Jackson DC; Cunningham AL
    J Immunol; 2012 May; 188(9):4158-70. PubMed ID: 22467654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro.
    Cunningham AL; Noble JR
    J Clin Invest; 1989 Feb; 83(2):490-6. PubMed ID: 2464000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to herpes simplex virus in patients with recurrent herpes labialis: I. Development of cell-mediated cytotoxic responses.
    Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Cohen E; Orsini F; Ogra PL
    Clin Exp Immunol; 1986 Dec; 66(3):507-15. PubMed ID: 2436840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human MHC-restricted cellular response to herpes simplex virus type 1 is mediated by CD4+, CD8- T cells and is restricted to the DR region of the MHC complex.
    Schmid DS
    J Immunol; 1988 May; 140(10):3610-6. PubMed ID: 2834445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological responses of patients with recurrent herpes genitalis.
    Sirianni MC; Bonomo R; Scarpati B; Soddu S; Panà A; Turbessi G; Cherchi M; Aiuti F
    Diagn Immunol; 1986; 4(6):294-8. PubMed ID: 3493109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer-mediated lysis of some but not all HSV-1- or VSV-infected targets requires the participation of HLA-DR-positive accessory cells.
    Howell DM; Fitzgerald-Bocarsly P
    Immunology; 1991 Mar; 72(3):443-7. PubMed ID: 1851136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions.
    Koelle DM; Abbo H; Peck A; Ziegweid K; Corey L
    J Infect Dis; 1994 May; 169(5):956-61. PubMed ID: 8169426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
    Yasukawa M; Zarling JM
    J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy.
    Bernstein DI; Harrison CJ; Jenski LJ; Myers MG; Stanberry LR
    J Immunol; 1991 May; 146(10):3571-7. PubMed ID: 1851194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.
    Koelle DM; Posavad CM; Barnum GR; Johnson ML; Frank JM; Corey L
    J Clin Invest; 1998 Apr; 101(7):1500-8. PubMed ID: 9525993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral inhibition of lymphocyte proliferative responsiveness in patients suffering from recurrent lesions caused by herpes simplex virus.
    Wainberg MA; Portnoy JD; Clecner B; Hubschman S; Lagacé-Simard J; Rabinovitch N; Remer Z; Mendelson J
    J Infect Dis; 1985 Sep; 152(3):441-8. PubMed ID: 2993440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to herpes simplex virus: virus reactivation modulates lymphokine activity.
    Sheridan JF; Beck M; Aurelian L; Radowsky M
    J Infect Dis; 1985 Sep; 152(3):449-56. PubMed ID: 2411825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological markers of frequently recurrent genital herpes simplex virus and their response to hypnotherapy: a pilot study.
    Fox PA; Henderson DC; Barton SE; Champion AJ; Rollin MS; Catalan J; McCormack SM; Gruzelier J
    Int J STD AIDS; 1999 Nov; 10(11):730-4. PubMed ID: 10563560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis.
    Bengtsson M; Tötterman TH; Smedmyr B; Festin R; Oberg G; Simonsson B
    Leukemia; 1989 Jan; 3(1):68-75. PubMed ID: 2535882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes.
    Mikloska Z; Cunningham AL
    J Gen Virol; 1998 Feb; 79 ( Pt 2)():353-61. PubMed ID: 9472620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional heterogeneity among herpes simplex virus-specific human CD4+ T cells.
    Yasukawa M; Inatsuki A; Horiuchi T; Kobayashi Y
    J Immunol; 1991 Feb; 146(4):1341-7. PubMed ID: 1671404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The interrelation of the expression of HLA class I and II proteins and of the costimulatory proteins CD11a/CD18 and CD16 with the lytic activity of resting and activated natural killer lymphocytes].
    Musatov MI; Petrova ED; Konenkov VI
    Tsitologiia; 1997; 39(7):617-28. PubMed ID: 9490502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of herpes simplex virus replication in vitro by human cytotoxic T cell clones and natural killer cell clones.
    Yasukawa M; Kobayashi Y
    J Gen Virol; 1985 Oct; 66 ( Pt 10)():2225-9. PubMed ID: 2995557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
    Karlsson FA; Tötterman TH
    Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.